CompletedPhase 2NCT02207062
Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Studying Indolent B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington
- Principal Investigator
- Ajay K. GopalFred Hutch/University of Washington Cancer Consortium
- Intervention
- Ibrutinib(drug)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2014 – 2023
Study locations (1)
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Collaborators
Janssen Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02207062 on ClinicalTrials.govOther trials for Indolent B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07166419Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic LeukemiaOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE1, PHASE2NCT07098364ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell LymphomaFred Hutchinson Cancer Center
- RECRUITINGPHASE1NCT06824701Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaUniversity of Utah
- RECRUITINGPHASE2NCT07030699A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07029217A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT06458439Epcoritamab-CAR T Cells for Large B-cell LymphomasAbramson Cancer Center at Penn Medicine
- RECRUITINGPHASE2NCT06442475Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06386315Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin LymphomaMayo Clinic